Northern Trust Corp Reduces Stake in Takeda Pharmaceutical Co. $TAK

Key Points

• Northern Trust Corp reduced its holdings in Takeda Pharmaceutical Co. by 12.5%, selling 233,675 shares and currently owns approximately 1.64 million shares worth $24.4 million.
• Takeda Pharmaceutical reported a quarterly earnings per share (EPS) of $0.52, exceeding analysts' expectations of $0.47, despite revenues falling short at $7.45 billion.
• Analysts have downgraded Takeda from a "hold" to a "strong sell" rating, with one analyst maintaining a Buy rating, indicating mixed opinions on the stock's performance.

Northern Trust Corp reduced its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 12.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,639,913 shares of the company's stock after selling 233,675 shares during the period. Northern Trust Corp owned 0.05% of Takeda Pharmaceutical worth $24,386,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. Brooklyn Investment Group raised its holdings in shares of Takeda Pharmaceutical by 890.7% during the first quarter. Brooklyn Investment Group now owns 12,176 shares of the company's stock worth $181,000 after purchasing an additional 10,947 shares during the period. Corient IA LLC bought a new stake in Takeda Pharmaceutical during the first quarter valued at about $595,000. American Century Companies Inc. lifted its stake in shares of Takeda Pharmaceutical by 5.0% in the first quarter. American Century Companies Inc. now owns 316,208 shares of the company's stock valued at $4,702,000 after buying an additional 15,121 shares during the period. Boston Partners increased its holdings in shares of Takeda Pharmaceutical by 91.2% during the first quarter. Boston Partners now owns 132,107 shares of the company's stock worth $1,964,000 after buying an additional 63,024 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Takeda Pharmaceutical during the 1st quarter worth $125,000. Institutional investors and hedge funds own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Up 1.0%

Shares of TAK stock traded up $0.16 during trading hours on Friday, reaching $15.45. 722,314 shares of the company's stock were exchanged, compared to its average volume of 2,542,660. Takeda Pharmaceutical Co. has a fifty-two week low of $12.80 and a fifty-two week high of $15.56. The company has a market cap of $49.15 billion, a price-to-earnings ratio of 51.48 and a beta of 0.22. The company has a current ratio of 1.16, a quick ratio of 0.59 and a debt-to-equity ratio of 0.60. The stock's 50 day moving average is $14.82 and its 200-day moving average is $14.77.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. The business had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Analysts predict that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Zacks Research downgraded shares of Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a research report on Thursday, August 21st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold".

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.